Loading...
The Women’s Health Initiative (WHI) study of daily estrogen (conjugated equine estrogen 0.625 mg) and progestin (medroxyprogesterone 2.5 mg) therapy was stopped in 2002 after 5.6 years because of a significantly higher risk for coronary artery disease, stroke, thromboembolic disease, and invasive breast cancer in the study subjects, who also had lower risks for osteoporotic fractures and colorectal cancer (Journal Watch Dec 31 2004). Roughly 95% of the original 15,730 participants (age range, 50–79 at enrollment) were available for follow-up 2.5 years after termination of the randomized, placebo-controlled study, or 8 years after its start.
During the 2.4-year postintervention period, annual rates of CAD, venous thromboembolic disease, strok…